Waters Corporation Is Tapping Into The Billion-Dollar Pharma Boom with Strategic Global Moves; Will It Work? 

Waters Corporation’s first quarter of 2025 showcased a mixed performance with notable strengths and specific challenges. The company marked a promising start to the year with robust instrument growth driven by expansive demand in pharma and industrial markets. Sales grew 4% as reported, and 7% on a constant currency basis, hitting the higher end of the company’s guidance. Instruments showed remarkable growth at 11%, led by robust mid-teens sales increases in liquid chromatography and mass spectrometry, underpinning strong demand primarily in pharma sectors.